Johnson & Johnson Hits Roadblock as Recruitment in Diabetes Drug Study From Hanmi Pharma is Halted

J&J has run into a problem with a Phase I diabetes drug — JNJ-64565111 — in-licensed from South Korea’s Hanmi. The investigators on the study reported on clinicaltrials.gov that the trial has suspended patient recruitment, and a spokesperson for J&J tells me that the delay was due to “a manufacturing-related delay.”

“Our partnership with Hanmi remains strong regarding this drug candidate and we look forward to restarting the study,” she added.

Hanmi has been bedeviled by issues surrounding olmutinib. The cancer drug was partnered with Boehringer Ingelheim, which abruptly canceled the deal following some toxic patient reactions and several reported deaths.

Back to news